GoodRx Holdings Hits 52-Week Low at $3.21 Amidst Significant Decline

GoodRx Holdings, Inc. has reached a new 52-week low, trading at USD 3.21 on November 4, 2025. This marks a significant decline for the microcap company, which operates in the Computers - Software & Consulting industry. Over the past year, GoodRx has experienced a performance drop of 63.41%, contrasting sharply with the S&P 500's gain of 19.89%.
Despite the recent downturn, GoodRx reported positive financial metrics earlier this year, including an operating cash flow of USD 190.59 million and a net profit of USD 28.24 million for the first half of the year. The company's return on equity stands at 7.01%, with a price-to-book ratio of 2.23, indicating an attractive valuation relative to its peers.

GoodRx's market capitalization is approximately USD 1.43 billion, and it maintains a debt-to-equity ratio of 0.33. Institutional investors hold a significant stake in the company, with ownership at 87.16%, reflecting confidence in its fundamentals. However, the stock's performance has been below par in both the long and short term, highlighting ongoing challenges for the company.